BNB Plus Corp. BNBX

Q3 FY2026 · ended Jun 30, 2026 · Revenue $605,306, +98.9% YoY · Filed Aug 13, 2026

BNB Plus Corp. (BNBX) files with the SEC under industry code 6199, Finance Services. In Q3 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $605,306 and a net loss of $4.7 million.

Revenue
$605,306
+98.9% vs year-ago quarter
Net income
$-4.69M
-18.8% vs year-ago quarter
Operating cash flow
$-982,922
+62.2% vs year-ago quarter
Free cash flow
$-2.61M
+22.6% vs year-ago quarter
EPS
$-0.57
+98.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
6.20M
+379.9% vs year-ago quarter
Net cash
$2.40M
Q1 FY2026
Operating margin
-1449.2%
TTM

Company profile

Industry
Finance Services (SIC 6199)
Listed as
BNBX (OTC)
Fiscal year ends
September 30
Incorporated in
DE
Headquarters
Stony Brook, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
744452
Former names
APPLIED DNA SCIENCES INC (until Nov 10, 2025); PROHEALTH MEDICAL TECHNOLOGIES INC (until Dec 18, 2002); DCC ACQUISITION CORP (until May 4, 2001); DATALINK CAPITAL CORP/TX/ (until Feb 8, 1999)

Other Finance Services companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Line
Q3 FY2026
Jun 30, 2026
Q2 FY2026
Mar 31, 2026
Q1 FY2026
Dec 31, 2025
Q4 FY2025
Sep 30, 2025
Q3 FY2025
Jun 30, 2025
Revenue
$605,306
$1.0M
$565,394
$199,429
$304,393
Operating income
-$3.2M
-$6.8M
-$18.7M
-$6.0M
-$3.7M
Net income
-$4.7M
-$6.7M
-$18.6M
-$5.3M
-$3.9M
Diluted EPS
-$0.57
-$0.68
-$2.08
-$4.03
-$34.00
Operating cash flow
-$982,922
-$2.0M
-$5.5M
-$3.1M
-$2.6M
Free cash flow
—
—
—
—
-$2.6M
Total assets
$15.0M
$13.6M
$20.7M
$4.4M
$9.9M
Total liabilities
$2.0M
$1.5M
$2.2M
$2.5M
$2.9M
Stockholders' equity
$9.5M
$12.5M
$18.8M
$2.3M
$7.3M
Cash and investments
$3.8M
$949,091
$2.5M
$1.7M
$4.7M
Total debt
—
—
$48,861
$193,250
$334,403

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K/A Amended current report
Material agreement
Oct 2, 2026 Sep 28, 2026
8-K Current report
Regulation FD disclosure
Oct 2, 2026 Oct 2, 2026
8-K Current report
Material agreement
Oct 1, 2026 Sep 28, 2026
8-K Current report
Officer or director change
Sep 3, 2026 Sep 2, 2026
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
8-K Current report
Material agreement, Agreement ended, Unregistered share sale, Officer or director change
Jul 29, 2026 Jul 23, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.